A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Ipsen
Cardiawave SA
Massachusetts General Hospital
Dermed Diagnostics, Inc.
Case Comprehensive Cancer Center
University of Alabama at Birmingham
National Institutes of Health Clinical Center (CC)
Janssen Research & Development, LLC
Klinikum Bremen-Mitte, gGmbH
City of Hope Medical Center
Direct Biologics, LLC
Innovent Biologics (Suzhou) Co. Ltd.
University of Nebraska
Massachusetts General Hospital
Fate Therapeutics
City of Hope Medical Center
Northwell Health
Hutchmed
Lyndra Inc.
biotx.ai GmbH
Boston University
Ohio State University Comprehensive Cancer Center
Incyte Corporation
Ohio State University Comprehensive Cancer Center
Medstar Health Research Institute
SecuraBio
Vanderbilt University Medical Center
Wake Forest University Health Sciences
CTI BioPharma
Louisiana State University Health Sciences Center Shreveport
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
Nordic Nanovector
University of Texas Southwestern Medical Center
Edwards Lifesciences
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of Arizona
Thesan Pharmaceuticals, Inc.
Northwestern University
Mayo Clinic
Rutgers, The State University of New Jersey
Northwestern University
University of Alabama at Birmingham
AIDS Malignancy Consortium
UNC Lineberger Comprehensive Cancer Center